A Downtrend for Balchem (NASDAQ:BCPC) on January 23rd, 2012 at $38.73. In approximately 2 months, Balchem has returned 22.67% as of today's recent price of $29.95.
Balchem share prices have moved between a 52-week high of $47.23 and a 52-week low of $26.56 and are now trading 13% above that low price at $29.95 per share. Over the last five market days, the 200-day moving average (MA) has gone down 0.4% while the 50-day MA has declined 2.1%.
Balchem Corporation develops, manufactures, and markets specialty performance ingredients for the food, feed, and medical sterilization industries. The Company micro-encapsulates performance ingredients, and also repackages and markets specialty gases. Balchem sells its products through its own sales force, independent distributors, and sales agents.
Top-News
Potenzial nach massiven Kurssturz Balchem (905650)
Beiträge: 41
Zugriffe: 22.873 / Heute: 7
Zugriffe: 22.873 / Heute: 7
|
| 15 Beiträge ausgeblendet. |
|
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers MSCI Pakistan Swap UCITS ETF 1C
Perf. 12M: +71,79%
Xtrackers S&P 500 2x Leveraged Daily Swap UCITS ETF 1C
Perf. 12M: +54,13%
Xtrackers MSCI USA Banks UCITS ETF 1D
Perf. 12M: +52,90%
Xtrackers Artificial Intelligence and Big Data UCITS ETF 1C
Perf. 12M: +51,26%
Xtrackers LPX Private Equity Swap UCITS ETF 1C
Perf. 12M: +49,72%
finance.yahoo.com/news/...ports-adjusted-ebitda-130000120.html
.
NEW HAMPTON, N.Y., May 10, 2016 (GLOBE NEWSWIRE) -- Balchem Corporation (BCPC) today reported for the first quarter 2016 adjusted EBITDA(a) of $35.5 million, compared to $36.1 million in the prior year quarter and $33.7 million sequentially from the fourth quarter 2015. Adjusted EBITDA margin expanded to 26.2% from 24.9% and 25.4% in the prior year quarter and fourth quarter 2015, respectively, and this was a significant contributor to these results in a challenging oil & gas and dairy market environment.
First Quarter 2016 Financial Highlights:
•Net sales of $135.1 million, a decrease of 6.7% compared to the first quarter of 2015, with the most significant driver of this decline being a $13.6 million reduction in sales in Industrial Products.
•Without the impact of Albion, record first quarter earnings for our Human Nutrition & Health (formerly SensoryEffects)(b) segment and record first quarter sales and record first quarter earnings for our Specialty Products(c) segment.
•Adjusted EBITDA margin improved to 26.2% versus 24.9% in the first quarter 2015 and 25.4% sequentially from the fourth quarter 2015 principally due to improved product mix and lower raw material costs.
•Adjusted earnings per share(a) of $0.58 decreased $0.04 or 6.5% from the prior year.
•Record first quarter cash flows from operations generated of $29.3 million.
.
NEW HAMPTON, N.Y., May 10, 2016 (GLOBE NEWSWIRE) -- Balchem Corporation (BCPC) today reported for the first quarter 2016 adjusted EBITDA(a) of $35.5 million, compared to $36.1 million in the prior year quarter and $33.7 million sequentially from the fourth quarter 2015. Adjusted EBITDA margin expanded to 26.2% from 24.9% and 25.4% in the prior year quarter and fourth quarter 2015, respectively, and this was a significant contributor to these results in a challenging oil & gas and dairy market environment.
First Quarter 2016 Financial Highlights:
•Net sales of $135.1 million, a decrease of 6.7% compared to the first quarter of 2015, with the most significant driver of this decline being a $13.6 million reduction in sales in Industrial Products.
•Without the impact of Albion, record first quarter earnings for our Human Nutrition & Health (formerly SensoryEffects)(b) segment and record first quarter sales and record first quarter earnings for our Specialty Products(c) segment.
•Adjusted EBITDA margin improved to 26.2% versus 24.9% in the first quarter 2015 and 25.4% sequentially from the fourth quarter 2015 principally due to improved product mix and lower raw material costs.
•Adjusted earnings per share(a) of $0.58 decreased $0.04 or 6.5% from the prior year.
•Record first quarter cash flows from operations generated of $29.3 million.
finance.yahoo.com/news/blachem-posts-4q-profit-132332147.html
seekingalpha.com/article/...chem-intact-long-term-growth-story
www.4-traders.com/...5-Million-and-First-Quarter-Adj-24352771/
www.4-traders.com/...e-beating-Walls-Streets-expecta-24895966/
www.4-traders.com/...h-Record-Third-Quarter-Net-Earn-25454884/
www.4-traders.com/...ith-Record-Net-Earnings-of-42-0-26067026/
www.4-traders.com/...illion-Record-First-Quarter-Net-26514877/
www.marketscreener.com/...chem-3Q-Earnings-Snapshot-27555451/
www.marketscreener.com/...d-Quarter-Net-Earnings-of-27554610/
www.marketscreener.com/...d-Quarter-Net-Earnings-of-27554610/
www.marketscreener.com/...es-of-163-5-million-Fourt-28085287/
02/28/2019 | 07:03am EST
Fourth quarter net sales of $163.5 million, growth of 2.7%, compared to prior year. Full year 2018 sales of $643.7 million, an increase of 8.2% from the prior year, with year over year sales growth in all four of our segments.
Fourth quarter GAAP EPS of $0.63, and adjusted EPS(a) of $0.77, an increase in adjusted EPS(a) of 13.2% compared to prior year. Full year GAAP EPS of $2.42, and adjusted EPS(a) of $3.01, an increase in adjusted EPS(a) of 19.0% from the prior year.
Fourth quarter cash flow from operations of $39.5 million and free cash flow(a) of $33.6 million, up 57.6% compared to prior year. Full year cash flow from operations of $118.7 million and free cash flow(a) of $99.5 million, up 19.8% compared to prior year.
02/28/2019 | 07:03am EST
Fourth quarter net sales of $163.5 million, growth of 2.7%, compared to prior year. Full year 2018 sales of $643.7 million, an increase of 8.2% from the prior year, with year over year sales growth in all four of our segments.
Fourth quarter GAAP EPS of $0.63, and adjusted EPS(a) of $0.77, an increase in adjusted EPS(a) of 13.2% compared to prior year. Full year GAAP EPS of $2.42, and adjusted EPS(a) of $3.01, an increase in adjusted EPS(a) of 19.0% from the prior year.
Fourth quarter cash flow from operations of $39.5 million and free cash flow(a) of $33.6 million, up 57.6% compared to prior year. Full year cash flow from operations of $118.7 million and free cash flow(a) of $99.5 million, up 19.8% compared to prior year.
www.globenewswire.com/news-release/2019/05/...EPS-of-0-73.html
www.marketscreener.com/...chem-3Q-Earnings-Snapshot-29517948/
www.balchem.com/wp-content/uploads/2020/...elease-Q4-2019.pdf
www.balchem.com/investor-relations/
Current Financials: Updated: February 21, 2020
• Fourth quarter net sales of $166.5 million, an increase of $3.0 million, or 1.8%, compared to the prior year quarter.
• Year over year quarterly sales growth in three of the four segments, with all-time record sales in Human Nutrition and Health and Animal Nutrition and Health, and record fourth quarter sales in Specialty Products.
• Fourth quarter GAAP net earnings of $20.4 million were slightly higher than the prior year. These net earnings resulted in GAAP earnings per share of $0.63.
• Quarterly adjusted net earnings of $28.4 million increased $3.3 million or 12.9% from the prior year, resulting in adjusted earnings per share of $0.88.
• Fourth quarter adjusted EBITDA was $40.0 million, an increase of $0.4 million, or 1.0%, from the prior year.
• Quarterly cash flows from operations were $33.0 million for the fourth quarter 2019 with quarterly free cash flow of $26.3 million.
Full Year 2019 Financial Highlights
• Full year net sales of $643.7 million were slightly higher than the prior year.
• Year over year sales growth in three of the four segments, with all-time record sales in Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products, offset by reduced sales in Industrial Products.
• Full year GAAP net earnings were $79.7 million, an increase of $1.1 million, or 1.4% from the prior year. These net earnings resulted in GAAP earnings per share of $2.45.
• Full year adjusted net earnings of $103.7 million increased $5.9 million or 6.1% from the prior year, resulting in adjusted earnings per share of $3.19.
• Full year adjusted EBITDA was $160.0 million, an increase of $0.7 million, or 0.5%, from the prior year.
• Full year cash flows from operations were $124.5 million for 2019 with full year free cash flow of $96.1 million.
www.balchem.com/investor-relations/
Current Financials: Updated: February 21, 2020
• Fourth quarter net sales of $166.5 million, an increase of $3.0 million, or 1.8%, compared to the prior year quarter.
• Year over year quarterly sales growth in three of the four segments, with all-time record sales in Human Nutrition and Health and Animal Nutrition and Health, and record fourth quarter sales in Specialty Products.
• Fourth quarter GAAP net earnings of $20.4 million were slightly higher than the prior year. These net earnings resulted in GAAP earnings per share of $0.63.
• Quarterly adjusted net earnings of $28.4 million increased $3.3 million or 12.9% from the prior year, resulting in adjusted earnings per share of $0.88.
• Fourth quarter adjusted EBITDA was $40.0 million, an increase of $0.4 million, or 1.0%, from the prior year.
• Quarterly cash flows from operations were $33.0 million for the fourth quarter 2019 with quarterly free cash flow of $26.3 million.
Full Year 2019 Financial Highlights
• Full year net sales of $643.7 million were slightly higher than the prior year.
• Year over year sales growth in three of the four segments, with all-time record sales in Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products, offset by reduced sales in Industrial Products.
• Full year GAAP net earnings were $79.7 million, an increase of $1.1 million, or 1.4% from the prior year. These net earnings resulted in GAAP earnings per share of $2.45.
• Full year adjusted net earnings of $103.7 million increased $5.9 million or 6.1% from the prior year, resulting in adjusted earnings per share of $3.19.
• Full year adjusted EBITDA was $160.0 million, an increase of $0.7 million, or 0.5%, from the prior year.
• Full year cash flows from operations were $124.5 million for 2019 with full year free cash flow of $96.1 million.
www.marketscreener.com/...chem-2Q-Earnings-Snapshot-31030373/
www.marketscreener.com/...Results-of-Operations-All-31032722/
www.marketscreener.com/...Results-of-Operations-All-31032722/
www.marketscreener.com/quote/stock/...ings-Snapshot-32481161/
seekingalpha.com/article/...&utm_source=twitter_automated
seekingalpha.com/article/...&utm_source=twitter_automated
Gelöschter Beitrag.
Einblenden
»
#33 
Blachem: Q2 Earnings Snapshot
07/30/2021 | 12:30pm BST
NEW HAMPTON, N.Y. (AP) _ Balchem Corp. (BCPC) on Friday reported second-quarter profit of $22.7 million.
On a per-share basis, the New Hampton, New York-based company said it had net income of 70 cents. Earnings, adjusted for one-time gains and costs, were 93 cents per share.
The chemical company posted revenue of $202.4 million in the period.
Blachem shares have increased 16% since the beginning of the year. The stock has increased 35% in the last 12 months.
This story was generated by Automated Insights (automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BCPC at www.zacks.com/ap/BCPC
Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News
www.marketscreener.com/quote/stock/...ings-Snapshot-36017411/
www.marketscreener.com/quote/stock/...perations-All-36023486/
07/30/2021 | 12:30pm BST
NEW HAMPTON, N.Y. (AP) _ Balchem Corp. (BCPC) on Friday reported second-quarter profit of $22.7 million.
On a per-share basis, the New Hampton, New York-based company said it had net income of 70 cents. Earnings, adjusted for one-time gains and costs, were 93 cents per share.
The chemical company posted revenue of $202.4 million in the period.
Blachem shares have increased 16% since the beginning of the year. The stock has increased 35% in the last 12 months.
This story was generated by Automated Insights (automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BCPC at www.zacks.com/ap/BCPC
Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News
www.marketscreener.com/quote/stock/...ings-Snapshot-36017411/
www.marketscreener.com/quote/stock/...perations-All-36023486/
de.marketscreener.com/kurs/aktie/...msatzsteigerung-42206953/
Balchem's Q3 bereinigtes Ergebnis, Umsatzsteigerung
04.11.2022 | 12:36
(MT Newswires) -- Balchem (BCPC) meldete am Freitag für das 3. Quartal einen bereinigten Gewinn von $1,00 je verwässerter Aktie, nach $0,92 im Vorjahr.
Einer von zwei von Capital IQ befragten Analysten hatte $1,03 erwartet.
Der Nettoumsatz für das Quartal, das am 30. September endete, betrug 244,3 Mio. $, verglichen mit 197,9 Mio. $ im Vorjahr.
Drei von Capital IQ befragte Analysten hatten 239,6 Millionen Dollar erwartet.
de.marketscreener.com/kurs/aktie/...msatzsteigerung-42206953/
Balchem's Q3 bereinigtes Ergebnis, Umsatzsteigerung
04.11.2022 | 12:36
(MT Newswires) -- Balchem (BCPC) meldete am Freitag für das 3. Quartal einen bereinigten Gewinn von $1,00 je verwässerter Aktie, nach $0,92 im Vorjahr.
Einer von zwei von Capital IQ befragten Analysten hatte $1,03 erwartet.
Der Nettoumsatz für das Quartal, das am 30. September endete, betrug 244,3 Mio. $, verglichen mit 197,9 Mio. $ im Vorjahr.
Drei von Capital IQ befragte Analysten hatten 239,6 Millionen Dollar erwartet.
de.marketscreener.com/kurs/aktie/...msatzsteigerung-42206953/
de.marketscreener.com/kurs/aktie/...s-Umsatzanstieg-43076829/
(MT Newswires) -- Balchem (BCPC) hat am Freitag für das vierte Quartal einen bereinigten Gewinn von $0,94 je verwässerter Aktie ausgewiesen, gegenüber $0,85 je Aktie im Vorjahr.
Ein einziger von Capital IQ befragter Analyst erwartete ein bereinigtes EPS von $0,91.
Der Nettoumsatz für das am 31. Dezember beendete Quartal belief sich auf 232,5 Mio. $, verglichen mit 213,1 Mio. $ vor einem Jahr. Drei von Capital IQ befragte Analysten hatten 241,5 Millionen Dollar erwartet.
(MT Newswires) -- Balchem (BCPC) hat am Freitag für das vierte Quartal einen bereinigten Gewinn von $0,94 je verwässerter Aktie ausgewiesen, gegenüber $0,85 je Aktie im Vorjahr.
Ein einziger von Capital IQ befragter Analyst erwartete ein bereinigtes EPS von $0,91.
Der Nettoumsatz für das am 31. Dezember beendete Quartal belief sich auf 232,5 Mio. $, verglichen mit 213,1 Mio. $ vor einem Jahr. Drei von Capital IQ befragte Analysten hatten 241,5 Millionen Dollar erwartet.
de.marketscreener.com/kurs/aktie/...t-Umsatz-steigt-43679893/
Balchem's Q1 bereinigter Gewinn sinkt, Umsatz steigt
28.04.2023 | 14:26
(MT Newswires) -- Balchem (BCPC) hat am Freitag für das erste Quartal einen bereinigten Gewinn von $0,94 pro verwässerter Aktie ausgewiesen, gegenüber $1,03 pro Aktie im Vorjahr.
Ein von Capital IQ befragter Analyst erwartete ein bereinigtes EPS von $0,82.
Der Nettoumsatz für das am 31. März beendete Quartal lag bei 232,5 Mio. $, gegenüber 228,9 Mio. $ im Vorjahr. Drei von Capital IQ befragte Analysten hatten $233,5 Millionen erwartet.
Balchem's Q1 bereinigter Gewinn sinkt, Umsatz steigt
28.04.2023 | 14:26
(MT Newswires) -- Balchem (BCPC) hat am Freitag für das erste Quartal einen bereinigten Gewinn von $0,94 pro verwässerter Aktie ausgewiesen, gegenüber $1,03 pro Aktie im Vorjahr.
Ein von Capital IQ befragter Analyst erwartete ein bereinigtes EPS von $0,82.
Der Nettoumsatz für das am 31. März beendete Quartal lag bei 232,5 Mio. $, gegenüber 228,9 Mio. $ im Vorjahr. Drei von Capital IQ befragte Analysten hatten $233,5 Millionen erwartet.
de.marketscreener.com/kurs/aktie/...-Umsatzruckgang-44453209/
Balchem's Q2 bereinigtes Ergebnis, Umsatzrückgang
Heute um 14:11
(MT Newswires) -- Balchem (BCPC) hat am Freitag für das 2. Quartal einen bereinigten Gewinn von $1,06 je verwässerter Aktie ausgewiesen, gegenüber $1,07 im Vorjahr.
Ein von Capital IQ befragter Analyst hatte 0,93 $ pro Aktie erwartet.
Der Nettoumsatz für das Quartal, das am 30. Juni endete, lag bei $ 231,3 Millionen, gegenüber $ 236,7 Millionen im Vorjahr.
Drei von Capital IQ befragte Analysten hatten 244,9 Millionen Dollar erwartet.
Balchem's Q2 bereinigtes Ergebnis, Umsatzrückgang
Heute um 14:11
(MT Newswires) -- Balchem (BCPC) hat am Freitag für das 2. Quartal einen bereinigten Gewinn von $1,06 je verwässerter Aktie ausgewiesen, gegenüber $1,07 im Vorjahr.
Ein von Capital IQ befragter Analyst hatte 0,93 $ pro Aktie erwartet.
Der Nettoumsatz für das Quartal, das am 30. Juni endete, lag bei $ 231,3 Millionen, gegenüber $ 236,7 Millionen im Vorjahr.
Drei von Capital IQ befragte Analysten hatten 244,9 Millionen Dollar erwartet.
de.marketscreener.com/kurs/aktie/...ttoumsatz-sinkt-45172656/
Balchem Q3 bereinigter Gewinn steigt, Nettoumsatz sinkt
Am 27. Oktober 2023 um 14:53 Uhr
(MT Newswires) -- Balchem (BCPC) meldete am Freitag für das 3. Quartal einen bereinigten Nettogewinn von $1,04 je verwässerter Aktie, gegenüber $1,00 im Vorjahr.
Zwei von Capital IQ befragte Analysten hatten $0,97 erwartet.
Der Nettoumsatz für das Quartal, das am 30. September endete, lag bei 229,9 Mio. $, gegenüber 244,3 Mio. $ im Vorjahresquartal.
Drei von Capital IQ befragte Analysten hatten $237,1 Millionen erwartet.
Balchem Q3 bereinigter Gewinn steigt, Nettoumsatz sinkt
Am 27. Oktober 2023 um 14:53 Uhr
(MT Newswires) -- Balchem (BCPC) meldete am Freitag für das 3. Quartal einen bereinigten Nettogewinn von $1,04 je verwässerter Aktie, gegenüber $1,00 im Vorjahr.
Zwei von Capital IQ befragte Analysten hatten $0,97 erwartet.
Der Nettoumsatz für das Quartal, das am 30. September endete, lag bei 229,9 Mio. $, gegenüber 244,3 Mio. $ im Vorjahresquartal.
Drei von Capital IQ befragte Analysten hatten $237,1 Millionen erwartet.
Balchem's Q4 bereinigtes Ergebnis steigt, Nettoumsatz sinkt
Am 16. Februar 2024 um 13:53 Uhr
(MT Newswires) -- Balchem (BCPC) meldete am Freitag für das vierte Quartal einen bereinigten Gewinn von $0,95 pro verwässerter Aktie, gegenüber $0,94 im Vorjahr.
Zwei von Capital IQ befragte Analysten hatten $0,93 erwartet.
Der Nettoumsatz für das Quartal, das am 31. Dezember endete, lag bei $228,7 Millionen, verglichen mit $232,5 Millionen im Jahr zuvor.
Die von Capital IQ befragten Analysten hatten $234,7 Millionen erwartet.
Am 16. Februar 2024 um 13:53 Uhr
(MT Newswires) -- Balchem (BCPC) meldete am Freitag für das vierte Quartal einen bereinigten Gewinn von $0,95 pro verwässerter Aktie, gegenüber $0,94 im Vorjahr.
Zwei von Capital IQ befragte Analysten hatten $0,93 erwartet.
Der Nettoumsatz für das Quartal, das am 31. Dezember endete, lag bei $228,7 Millionen, verglichen mit $232,5 Millionen im Jahr zuvor.
Die von Capital IQ befragten Analysten hatten $234,7 Millionen erwartet.
de.marketscreener.com/kurs/aktie/...msatzsteigerung-46622585/
Balchem Q1 bereinigter Nettogewinn, Umsatzsteigerung
Am 03. Mai 2024 um 14:11 Uhr
(MT Newswires) -- Balchem (BCPC) meldete am Freitag für das erste Quartal einen bereinigten Nettogewinn von $1,03 pro verwässerter Aktie, nach $0,94 im Vorjahr.
Zwei von Capital IQ befragte Analysten hatten $0,98 erwartet.
Der Nettoumsatz für das Quartal, das am 31. März endete, lag bei $239,7 Millionen, verglichen mit $232,5 Millionen im Vorjahr.
Zwei von Capital IQ befragte Analysten hatten $232,5 Millionen erwartet.
Balchem Q1 bereinigter Nettogewinn, Umsatzsteigerung
Am 03. Mai 2024 um 14:11 Uhr
(MT Newswires) -- Balchem (BCPC) meldete am Freitag für das erste Quartal einen bereinigten Nettogewinn von $1,03 pro verwässerter Aktie, nach $0,94 im Vorjahr.
Zwei von Capital IQ befragte Analysten hatten $0,98 erwartet.
Der Nettoumsatz für das Quartal, das am 31. März endete, lag bei $239,7 Millionen, verglichen mit $232,5 Millionen im Vorjahr.
Zwei von Capital IQ befragte Analysten hatten $232,5 Millionen erwartet.
|
Neueste Beiträge aus dem Balchem Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
3 | 40 | Potenzial nach massiven Kurssturz Balchem (905650) | raketentrader | Tamakoschy | 03.05.24 16:35 |
